Immunotherapy Drugs Market

Immunotherapy Drugs Market (Drug Type: Monoclonal Antibodies, Immunomodulators, Cell Therapy and Others; and Therapy Area: Cancer, Autoimmune Diseases, Infectious Diseases, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Immunotherapy Drugs Market Outlook 2031

  • The global industry was valued at US$ 126.4 Bn in 2022
  • It is projected to grow at a CAGR of 7.1% from 2023 to 2031 and reach more than US$ 237.4 Bn by 2031

Analyst Viewpoint

Advancements in cancer treatment and growth in understanding of the immune system's role in combating diseases are propelling the immunotherapy drugs market size. The market is witnessing a surge in research and development activities, leading to the introduction of innovative therapies. Key players in the pharmaceutical industry are focusing on expanding their immunotherapy portfolios to address various cancers and improve patient outcomes.

One notable trend in the immunotherapy drugs market landscape is the emergence of combination therapies, where different immunotherapeutic agents are used together or in conjunction with traditional treatments. This approach aims to enhance the overall effectiveness of immunotherapy and broaden its applicability across different cancer types.

Immunotherapy Drugs Market

Market Introduction

Immunotherapy is a type of medical treatment that stimulates the body's immune system to fight diseases, including cancer. Immunotherapy drugs are designed to enhance or modify the immune system's response to target and eliminate abnormal cells. Immunotherapy is used to treat various cancers including melanoma, Non-small Cell Lung Cancer (NSCLC), and Head and Neck Squamous Cell Carcinoma (HNSCC). It targets the PD-1 protein in immune cells, allowing them to attack cancer cells more effectively. Immunotherapy is employed in the treatment of certain types of lymphoma and leukemia. It involves modifying a patient's own T cells to express a Chimeric Antigen Receptor (CAR) that targets cancer cells.

Advancements in Biotechnology and Personalized Medicines Fueling Immunotherapy Drugs Market Value

Traditional treatments often rely on a one-size-fits-all approach, which may not be effective for every patient. Immunotherapy, on the other hand, leverages the body's immune system to target specific abnormalities, offering a more tailored and effective treatment.

Biotechnological advancements have played a pivotal role in the development of immunotherapeutic drugs, enabling the creation of novel therapies that can selectively target cancer cells, autoimmune disorders, and other diseases. Breakthroughs in genetic sequencing, biomarker identification, and understanding the immune system's complexities have paved the way for personalized immunotherapies. As a result, pharmaceutical companies are increasingly investing in research and development to create innovative drugs that can be customized based on an individual's genetic makeup, ensuring better treatment outcomes. The integration of biomarkers in immunotherapy research has facilitated the identification of patients who are more likely to respond positively to specific treatments.

High Demand for Monoclonal Antibodies Propelling Market Progress

According to the latest immunotherapy drugs market trends, the monoclonal antibodies drug type segment held largest share in 2022. Monoclonal antibodies are laboratory-produced molecules designed to mimic the immune system's ability to fight off harmful pathogens, including cancer cells. They can be used for various therapeutic purposes such as cancer treatment.

These mAbs block specific proteins on immune cells or cancer cells, preventing them from inhibiting the immune system's ability to attack cancer. Examples include pembrolizumab, nivolumab, and ipilimumab. Some mAbs are designed to bind directly to cancer cells, marking them for destruction by the immune system or delivering signals that trigger cell death.

Extensive Use of Immunotherapy Drugs in Cancer Treatment

According to the latest immunotherapy drugs market analysis, the cancer therapy area segment held largest share in 2022. Immunotherapy has become a prominent and rapidly growing area within cancer therapy. Immunotherapy, which includes treatments like immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, has shown promising results in various types of cancers by harnessing the body's immune system to target and eliminate cancer cells.

Immunotherapy has demonstrated notable success in treating certain cancers, with durable responses and improved overall survival rates in some cases. Several immunotherapy drugs, such as pembrolizumab, nivolumab, and ipilimumab, have gained approval for treating various cancers, leading to increased adoption in clinical practice. Continuous research and development efforts in the field of immunotherapy have resulted in the identification of new targets and the development of novel therapeutic approaches, expanding the range of treatable cancers.

Surge in Distribution of Immunotherapy Drugs in Retail Pharmacies

According to the latest immunotherapy drugs market research, the retail pharmacies distribution channel segment accounted for major share in 2022. The choice of distribution channel can depend on several factors, including the nature of the drug, patient access, and regulatory considerations. Retail pharmacies may be more suitable for certain types of immunotherapy drugs, especially those that can be administered or self-administered on an outpatient basis.

Regional Immunotherapy Drugs Market Insights

North America accounted for the largest immunotherapy drugs industry share in 2022. The U.S. is a significant contributor to the industry in the region, with a well-established healthcare system and a high prevalence of cancer. Rise in investment in clinical trials and research activities is propelling the immunotherapy drugs market dynamics in North America. Regulatory agencies such as the FDA play a crucial role in approving and fast-tracking immunotherapy drugs.

Growth in cancer incidence, improvement in healthcare infrastructure, and increase in investment in research and development are driving the immunotherapy drugs market expansion in Asia Pacific. China, Japan, and India are major markets for immunotherapy drugs in the region. Access to immunotherapies may vary across countries due to economic disparities.

Analysis of Key Players

Immunotherapy drug manufacturers are adopting various strategies, such as new product launches, mergers, partnerships, and collaborations, to strengthen their position Bristol Myers Squibb, Merck KGaA, Inc., F. Hoffmann-La Roche AG, Novartis AG, AstraZeneca, Pfizer, Amgen, Gilead Sciences, Eli Lilly and Company, and Regeneron Pharmaceuticals Inc. are the prominent players in this market.

Each of these companies has been profiled in the immunotherapy drugs market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.

Key Developments in Global Immunotherapy Drugs Industry

  • In September 2023, NextCure announced the initiation of a Phase I/II trial (NCT03665285) to evaluate the safety and tolerability of NC318 as a potential treatment for advanced or metastatic solid tumors. The trial includes assessments for conditions such as head and neck squamous cell carcinoma, non-small cell lung cancer, and ovarian cancer.
  • In January 2023, BioNTech SE signed a Memorandum of Understanding ("MoU") with the U.K. government to expedite clinical trials for personalized mRNA immunotherapies. The goal is to offer personalized cancer therapies to as many as 10,000 patients by the conclusion of 2030, whether in clinical trials or as approved treatments, for the benefit of patients.

Global Immunotherapy Drugs Market Snapshot

Attribute Detail
Market Size in 2022 US$ 126.4 Bn
Market Forecast (Value) in 2031 More than US$ 237.4 Bn
Growth Rate (CAGR) 7.1%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.
Competition Landscape Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Drug Type
    • Monoclonal Antibodies
    • Immunomodulators
    • Cell Therapy
    • Others (Vaccines, etc.)
  • Therapy Area
    • Cancer
    • Autoimmune Diseases
    • Infectious Diseases
    • Others
  • Distribution Channel
    • Retail Pharmacies
    • Online Pharmacies
    • Hospital Pharmacies
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa
Companies Profiled
  • Bristol Myers Squibb
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • AstraZeneca
  • Pfizer
  • Amgen
  • Gilead Sciences
  • Regeneron Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Others
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global immunotherapy drugs market in 2022?

It was valued at US$ 126.4 Bn in 2022

How big is the immunotherapy drugs industry expected to be by 2031?

It is projected to reach more than US$ 237.4 Bn by the end of 2031

What is the CAGR of the immunotherapy drugs business projected to be during the forecast period?

It is anticipated to be 7.1% from 2023 to 2031

What are the prominent factors fueling the demand for immunotherapy drugs?

Advancements in biotechnology and personalized medicines

Which was the largest immunotherapy drugs segment in 2022?

The monoclonal antibodies drug type segment accounted for major share in 2022

Which region is likely to record significant share in the immunotherapy drugs sector during the forecast period?

North America is expected to account for major share during the forecast period

Who are the prominent immunotherapy drug manufacturers?

Bristol Myers Squibb, Merck KGaA, Inc., F. Hoffmann-La Roche AG, Novartis AG, AstraZeneca, Pfizer, Amgen, Gilead Sciences, Eli Lilly and Company, and Regeneron Pharmaceuticals Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Immunotherapy Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

        4.3.4. Global Immunotherapy Drugs Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Key Industry Events

    5.3. COVID-19 Impact Analysis

6. Global Immunotherapy Drugs Market Analysis and Forecast, by Drug Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Type, 2017–2031

        6.3.1. Monoclonal Antibodies

        6.3.2. Immunomodulators

        6.3.3. Cell Therapy

        6.3.4. Others (Vaccines, etc.)

    6.4. Market Attractiveness Analysis, by Drug Type

7. Global Immunotherapy Drugs Market Analysis and Forecast, by Therapy Area

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Therapy Area, 2017–2031

        7.3.1. Cancer

        7.3.2. Autoimmune Diseases

        7.3.3. Infectious Diseases

        7.3.4. Others

    7.4. Market Attractiveness Analysis, by Therapy Area

8. Global Immunotherapy Drugs Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Retail Pharmacies

        8.3.2. Online Pharmacies

        8.3.3. Hospital Pharmacies

9. Global Immunotherapy Drugs Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Immunotherapy Drugs Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Type, 2017–2031

        10.2.1. Monoclonal Antibodies

        10.2.2. Immunomodulators

        10.2.3. Cell Therapy

        10.2.4. Others (Vaccines, etc.)

    10.3. Market Value Forecast, by Therapy Area, 2017–2031

        10.3.1. Cancer

        10.3.2. Autoimmune Diseases

        10.3.3. Infectious Diseases

        10.3.4. Others

    10.4. Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Retail Pharmacies

        10.4.2. Online Pharmacies

        10.4.3. Hospital Pharmacies

    10.5. Market Attractiveness Analysis

        10.5.1. By Drug Type

        10.5.2. By Therapy Area

        10.5.3. By Distribution Channel

        10.5.4. By Country

11. Europe Immunotherapy Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Type, 2017–2031

        11.2.1. Monoclonal Antibodies

        11.2.2. Immunomodulators

        11.2.3. Cell Therapy

        11.2.4. Others (Vaccines, etc.)

    11.3. Market Value Forecast, by Therapy Area, 2017–2031

        11.3.1. Cancer

        11.3.2. Autoimmune Diseases

        11.3.3. Infectious Diseases

        11.3.4. Others

    11.4. Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Retail Pharmacies

        11.4.2. Online Pharmacies

        11.4.3. Hospital Pharmacies

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Drug Type

        11.6.2. By Therapy Area

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Immunotherapy Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Type, 2017–2031

        12.2.1. Monoclonal Antibodies

        12.2.2. Immunomodulators

        12.2.3. Cell Therapy

        12.2.4. Others (Vaccines, etc.)

    12.3. Market Value Forecast, by Therapy Area, 2017–2031

        12.3.1. Cancer

        12.3.2. Autoimmune Diseases

        12.3.3. Infectious Diseases

        12.3.4. Others

    12.4. Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Retail Pharmacies

        12.4.2. Online Pharmacies

        12.4.3. Hospital Pharmacies

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Drug Type

        12.6.2. By Therapy Area

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Immunotherapy Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Type, 2017–2031

        13.2.1. Monoclonal Antibodies

        13.2.2. Immunomodulators

        13.2.3. Cell Therapy

        13.2.4. Others (Vaccines, etc.)

    13.3. Market Value Forecast, by Therapy Area, 2017–2031

        13.3.1. Cancer

        13.3.2. Autoimmune Diseases

        13.3.3. Infectious Diseases

        13.3.4. Others

    13.4. Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Retail Pharmacies

        13.4.2. Online Pharmacies

        13.4.3. Hospital Pharmacies

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Drug Type

        13.6.2. By Therapy Area

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Immunotherapy Drugs Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Type, 2017–2031

        14.2.1. Monoclonal Antibodies

        14.2.2. Immunomodulators

        14.2.3. Cell Therapy

        14.2.4. Others (Vaccines, etc.)

    14.3. Market Value Forecast, by Therapy Area, 2017–2031

        14.3.1. Cancer

        14.3.2. Autoimmune Diseases

        14.3.3. Infectious Diseases

        14.3.4. Others

    14.4. Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Retail Pharmacies

        14.4.2. Online Pharmacies

        14.4.3. Hospital Pharmacies

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Drug Type

        14.6.2. By Therapy Area

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Global Immunotherapy Drugs Market, Company Share Analysis (2022)

    15.2. Company Profiles

        15.2.1. Bristol Myers Squibb

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Product Portfolio

            15.2.1.3. Financial Overview

            15.2.1.4. SWOT Analysis

            15.2.1.5. Strategic Overview

        15.2.2. Merck KGaA, Inc.

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Product Portfolio

            15.2.2.3. Financial Overview

            15.2.2.4. SWOT Analysis

            15.2.2.5. Strategic Overview

        15.2.3. Novartis AG

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Product Portfolio

            15.2.3.3. Financial Overview

            15.2.3.4. SWOT Analysis

            15.2.3.5. Strategic Overview

        15.2.4. AstraZeneca

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Product Portfolio

            15.2.4.3. Financial Overview

            15.2.4.4. SWOT Analysis

            15.2.4.5. Strategic Overview

        15.2.5. Pfizer

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Product Portfolio

            15.2.5.3. Financial Overview

            15.2.5.4. SWOT Analysis

            15.2.5.5. Strategic Overview

        15.2.6. Amgen

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Product Portfolio

            15.2.6.3. Financial Overview

            15.2.6.4. SWOT Analysis

            15.2.6.5. Strategic Overview

        15.2.7. Gilead Sciences

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.7.2. Product Portfolio

            15.2.7.3. Financial Overview

            15.2.7.4. SWOT Analysis

            15.2.7.5. Strategic Overview

        15.2.8. Regeneron Pharmaceuticals Inc.

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Product Portfolio

            15.2.8.3. Financial Overview

            15.2.8.4. SWOT Analysis

            15.2.8.5. Strategic Overview

        15.2.9. F. Hoffmann-La Roche AG

            15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.9.2. Product Portfolio

            15.2.9.3. Financial Overview

            15.2.9.4. SWOT Analysis

            15.2.9.5. Strategic Overview

        15.2.10. Eli Lilly and Company

            15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.10.2. Product Portfolio

            15.2.10.3. Financial Overview

            15.2.10.4. SWOT Analysis

            15.2.10.5. Strategic Overview

List of Tables

Table 01: Global Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 02: Global Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Therapy Area, 2017-2031

Table 03: Global Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 04: Global Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 05: North America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 06: North America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 07: North America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Therapy Area, 2017-2031

Table 08: North America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 09: Europe Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 10: Europe Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 11: Europe Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Therapy Area, 2017-2031

Table 12: Europe Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 13: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 14: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 15: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Therapy Area, 2017-2031

Table 16: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 17: Latin America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 18: Latin America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 19: Latin America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Therapy Area, 2017-2031

Table 20: Latin America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 21: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 23: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Therapy Area, 2017-2031

Table 24: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

Figure 01: Global Immunotherapy Drugs Market Value (US$ Mn) Forecast, 2017-2031

Figure 02: Global Immunotherapy Drugs Market Value Share, by Region, 2022

Figure 03: Global Immunotherapy Drugs Market Value Share, by Drug Type, 2022

Figure 04: Global Immunotherapy Drugs Market Value Share, by Therapy Area, 2022

Figure 05: Global Immunotherapy Drugs Market Value Share, by Distribution Channel, 2022

Figure 06: Global Immunotherapy Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 07: Global Immunotherapy Drugs Market Value Share Analysis, by Drug Type, 2022

Figure 08: Global Immunotherapy Drugs Market Value Share Analysis, by Drug Type, 2031

Figure 09: Global Immunotherapy Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 10: Global Immunotherapy Drugs Market Value (US$ Mn), by Monoclonal Antibodies, 2017‒2031

Figure 11: Global Immunotherapy Drugs Market Value Share Analysis, by Monoclonal Antibodies, 2022 and 2031

Figure 12: Global Immunotherapy Drugs Market Value (US$ Mn), by Immunomodulators, 2017‒2031

Figure 13: Global Immunotherapy Drugs Market Value Share Analysis, by Immunomodulators, 2022 and 2031

Figure 14: Global Immunotherapy Drugs Market Value (US$ Mn), by Cell Therapy, 2017‒2031

Figure 15: Global Immunotherapy Drugs Market Value Share Analysis, by Cell Therapy, 2022 and 2031

Figure 16: Global Immunotherapy Drugs Market Value (US$ Mn), by Others, 2017‒2031

Figure 17: Global Immunotherapy Drugs Market Value Share Analysis, by Others, 2022 and 2031

Figure 18: Global Immunotherapy Drugs Market Value Share Analysis, by Therapy Area, 2022 and 2031

Figure 19: Global Immunotherapy Drugs Market Value Share Analysis, by Therapy Area, 2022

Figure 20: Global Immunotherapy Drugs Market Value Analysis, by Therapy Area, 2031

Figure 21: Global Immunotherapy Drugs Market Attractiveness Analysis, by Therapy Area, 2023–2031

Figure 22: Global Immunotherapy Drugs Market Value (US$ Mn), by Cancer, 2017‒2031

Figure 23: Global Immunotherapy Drugs Market Value Share Analysis, by Cancer, 2022 and 2031

Figure 24: Global Immunotherapy Drugs Market Value (US$ Mn), by Autoimmune Diseases, 2017‒2031

Figure 24: Global Immunotherapy Drugs Market Value Share Analysis, by Autoimmune Diseases, 2022 and 2031

Figure 25: Global Immunotherapy Drugs Market Value (US$ Mn), by Autoimmune Diseases, 2017‒2031

Figure 25: Global Immunotherapy Drugs Market Value Share Analysis, by Autoimmune Diseases, 2022 and 2031

Figure 26: Global Immunotherapy Drugs Market Value (US$ Mn), by Others, 2017‒2031

Figure 27: Global Immunotherapy Drugs Market Value Share Analysis, by Others, 2022 and 2031

Figure 28: Global Immunotherapy Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 29: Global Immunotherapy Drugs Market Value Share Analysis, by Distribution Channel, 2022

Figure 30: Global Immunotherapy Drugs Market Value Share Analysis, by Distribution Channel, 2031

Figure 31: Global Immunotherapy Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 32: Global Immunotherapy Drugs Market Value (US$ Mn), by Retail Pharmacies, 2017‒2031

Figure 33: Global Immunotherapy Drugs Market Value Share Analysis, by Retail Pharmacies, 2022 and 2031

Figure 34: Global Immunotherapy Drugs Market Value (US$ Mn), by Online Pharmacies, 2017‒2031

Figure 35: Global Immunotherapy Drugs Market Value Share Analysis, by Online Pharmacies, 2022 and 2031

Figure 36: Global Immunotherapy Drugs Market Value (US$ Mn), by Hospital Pharmacies, 2017‒2031

Figure 36: Global Immunotherapy Drugs Market Value Share Analysis, by Hospital Pharmacies, 2022 and 2031

Figure 37: Global Immunotherapy Drugs Market Value Share Analysis, by Region, 2022 and 2031

Figure 38: Global Immunotherapy Drugs Market Value Share Analysis, by Region, 2022

Figure 39: Global Immunotherapy Drugs Market Value Analysis, by Region, 2031

Figure 40: Global Immunotherapy Drugs Market Attractiveness Analysis, by Region, 2023–2031

Figure 41: North America Immunotherapy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

Figure 42: North America Immunotherapy Drugs Market Value Share Analysis, by Country, 2022 and 2031

Figure 43: North America Immunotherapy Drugs Market Attractiveness Analysis, by Country, 2023–2031

Figure 44: North America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022 and 2031

Figure 45: North America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022

Figure 46: North America Immunotherapy Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 47: North America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022 and 2031

Figure 48: North America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022

Figure 49: North America Immunotherapy Drugs Market Attractiveness Analysis, by Therapy Area, 2023–2031

Figure 50: North America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022 and 2031

Figure 51: North America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022

Figure 52: North America Immunotherapy Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 53: Europe Immunotherapy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

Figure 54: Europe Immunotherapy Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 55: Europe Immunotherapy Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 56: Europe Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022 and 2031

Figure 57: Europe Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022

Figure 58: Europe Immunotherapy Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 59: Europe Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022 and 2031

Figure 60: Europe Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022

Figure 61: Europe Immunotherapy Drugs Market Attractiveness Analysis, by Therapy Area, 2023–2031

Figure 62: Europe Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022 and 2031

Figure 63: Europe Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022

Figure 64: Europe Immunotherapy Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 65: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

Figure 66: Asia Pacific Immunotherapy Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 67: Asia Pacific Immunotherapy Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 68: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022 and 2031

Figure 69: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022

Figure 70: Asia Pacific Immunotherapy Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 71: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022 and 2031

Figure 72: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022

Figure 73: Asia Pacific Immunotherapy Drugs Market Attractiveness Analysis, by Therapy Area, 2023–2031

Figure 74: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022 and 2031

Figure 75: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022

Figure 76: Asia Pacific Immunotherapy Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 77: Latin America Immunotherapy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

Figure 78: Latin America Immunotherapy Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 79: Latin America Immunotherapy Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 80: Latin America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022 and 2031

Figure 81: Latin America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022

Figure 82: Latin America Immunotherapy Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 83: Latin America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022 and 2031

Figure 84: Latin America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022

Figure 85: Latin America Immunotherapy Drugs Market Attractiveness Analysis, by Therapy Area, 2023–2031

Figure 86: Latin America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022 and 2031

Figure 87: Latin America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022

Figure 88: Latin America Immunotherapy Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 89 Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

Figure 90: Middle East & Africa Immunotherapy Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 91: Middle East & Africa Immunotherapy Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 92: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022 and 2031

Figure 93: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022

Figure 94: Middle East & Africa Immunotherapy Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 95: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022 and 2031

Figure 96: Middle East & Africa Immunotherapy Drugs Market Attractiveness Analysis, by Therapy Area, 2023–2031

Figure 97: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022

Figure 98: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022 and 2031

Figure 99: Middle East & Africa Immunotherapy Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 100: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved